語系:
繁體中文
English
說明(常見問題)
圖資館首頁
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Clinical xenotransplantationpathways...
~
Byrne, Guerard.
Clinical xenotransplantationpathways and progress in the transplantation of organs and tissues between species /
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Clinical xenotransplantationedited by David K. C. Cooper, Guerard Byrne.
其他題名:
pathways and progress in the transplantation of organs and tissues between species /
其他作者:
Cooper, David K. C.
出版者:
Cham :Springer International Publishing :2020.
面頁冊數:
xxix, 306 p. :ill., digital ;24 cm.
Contained By:
Springer Nature eBook
標題:
Xenografts.
電子資源:
https://doi.org/10.1007/978-3-030-49127-7
ISBN:
9783030491277$q(electronic bk.)
Clinical xenotransplantationpathways and progress in the transplantation of organs and tissues between species /
Clinical xenotransplantation
pathways and progress in the transplantation of organs and tissues between species /[electronic resource] :edited by David K. C. Cooper, Guerard Byrne. - Cham :Springer International Publishing :2020. - xxix, 306 p. :ill., digital ;24 cm.
Clinical and Experimental Xenotransplantation: Background -- 1. A brief history of clinical cross-species organ xenotransplantation -- 2. The pathobiology of pig-to-primate xenotransplantation: a historical review -- 3. Is sensitization to pig antigens detrimental to subsequent allotransplantation? -- 4. Sensitization to human leukocyte antigens and xenotransplantation? -- Pig Kidney and Heart Xenotransplantation in Nonhuman Primates - the Present Position -- 5. Kidney xenotransplantation in nonhuman primates -- 6. Cardiac xenotransplantation in nonhuman primates -- Organ-source Pig Genetic Engineering and Regulation -- 7. Gene-edited pigs for xenotransplantation -- 8. Addressing regulatory requirements for the organ-source pig - a pragmatic approach to facility design and pathogen prevention -- Antibody-Mediated Allotransplant Rejection: Lessons for Xenotransplantation -- 9. Antibody-mediated graft rejection in nonhuman primate models: comparison of sensitized allotransplant and xenotransplant rejection -- 10. Management of anti-HLA antibodies and acute antibody-mediated rejection -- 11. Evolving approaches to treatment of allosensitization and antibody-mediated rejection -- 12. Lessons from ABO-incompatible cardiac allotransplantation in the newborn -- Patient Evaluation and Selection for First Clinical Trials of Kidney or Heart Xenotransplantation -- 13. Defining an "acceptable risk threshold" - who should be the first kidney xenotransplant recipient? -- 14. Selection of patients for initial clinical trials of kidney xenotransplantation -- 15. Selection of patients for initial clinical trials of cardiac xenotransplantation -- 16. Selection of pediatric patients for initial clinical trials of cardiac xenotransplantation -- 17. Infection in xenotransplantation: organ-source health and patient safety -- 18. Histocompatibility testing for xenotransplantation -- Regulatory, Economic, and Social Aspects of Clinical Trials of Xenotransplantation -- 19. Xenotransplantation; the FDA perspective -- 20. Xenotransplantation: a payer's perspective -- 21. Public perceptions towards clinical trials of organ xenotransplantation -- Summation -- 22. What did the workshop achieve?
This title provides an illuminating examination of the current state of xenotransplantation - grafting or transplanting organs or tissues between members of different species - and how it might move forward into the clinic. To be sure, this is a critical topic, as a major problem that remains worldwide is an inadequate supply of organs from deceased human donors, severely limiting the number of organ transplants that can be performed each year. Based on presentations given at a major conference on xenotransplantation, this title includes important views from many leading experts who were invited to present their data and opinions on how xenotransplantation can advance into the clinic. Attention was concentrated on pig kidney and heart transplantation as it is in regard to these organs that most progress has been made. Collectively, these chapters effectively highlight the many advantages of xenotransplantation to patients with end-stage organ failure, thereby encouraging the mapping of a concrete pathway to clinical xenotransplantation. The book is organized across 22 chapters, beginning with background information on clinical and experimental xenotransplantation. Following this are discussions addressing how pigs can be genetically engineered for their organs to be resistant to the human immune response through deletion of pig xenoantigens, and the insertion of 'protective' human transgenes. Subsequent chapters analyze complications that arise in practice, comparing allotransplant and xenotransplant rejection. The selection of the ideal patients for the first clinical trials is discussed. Finally, the book concludes with an analysis on the regulatory, economic, and social aspects of this research, including FDA perspectives and the sensitive, psychosocial factors regarding allotransplantation and xenotransplantation. A major and timely addition to the literature, Clinical Xenotransplantation will be of great interest to all researchers, physicians, and academics from other disciplines with an interest in xenotransplantation.
ISBN: 9783030491277$q(electronic bk.)
Standard No.: 10.1007/978-3-030-49127-7doiSubjects--Topical Terms:
791409
Xenografts.
LC Class. No.: QR188.8 / .C556 2020
Dewey Class. No.: 617.954
National Library of Medicine Call No.: WO 660
Clinical xenotransplantationpathways and progress in the transplantation of organs and tissues between species /
LDR
:05339nmm a2200337 a 4500
001
586281
003
DE-He213
005
20210128171012.0
006
m d
007
cr nn 008maaau
008
210323s2020 sz s 0 eng d
020
$a
9783030491277$q(electronic bk.)
020
$a
9783030491260$q(paper)
024
7
$a
10.1007/978-3-030-49127-7
$2
doi
035
$a
978-3-030-49127-7
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
QR188.8
$b
.C556 2020
060
4
$a
WO 660
072
7
$a
MN
$2
bicssc
072
7
$a
MED085000
$2
bisacsh
072
7
$a
MN
$2
thema
082
0 4
$a
617.954
$2
23
090
$a
QR188.8
$b
.C641 2020
245
0 0
$a
Clinical xenotransplantation
$h
[electronic resource] :
$b
pathways and progress in the transplantation of organs and tissues between species /
$c
edited by David K. C. Cooper, Guerard Byrne.
260
$a
Cham :
$b
Springer International Publishing :
$b
Imprint: Springer,
$c
2020.
300
$a
xxix, 306 p. :
$b
ill., digital ;
$c
24 cm.
505
0
$a
Clinical and Experimental Xenotransplantation: Background -- 1. A brief history of clinical cross-species organ xenotransplantation -- 2. The pathobiology of pig-to-primate xenotransplantation: a historical review -- 3. Is sensitization to pig antigens detrimental to subsequent allotransplantation? -- 4. Sensitization to human leukocyte antigens and xenotransplantation? -- Pig Kidney and Heart Xenotransplantation in Nonhuman Primates - the Present Position -- 5. Kidney xenotransplantation in nonhuman primates -- 6. Cardiac xenotransplantation in nonhuman primates -- Organ-source Pig Genetic Engineering and Regulation -- 7. Gene-edited pigs for xenotransplantation -- 8. Addressing regulatory requirements for the organ-source pig - a pragmatic approach to facility design and pathogen prevention -- Antibody-Mediated Allotransplant Rejection: Lessons for Xenotransplantation -- 9. Antibody-mediated graft rejection in nonhuman primate models: comparison of sensitized allotransplant and xenotransplant rejection -- 10. Management of anti-HLA antibodies and acute antibody-mediated rejection -- 11. Evolving approaches to treatment of allosensitization and antibody-mediated rejection -- 12. Lessons from ABO-incompatible cardiac allotransplantation in the newborn -- Patient Evaluation and Selection for First Clinical Trials of Kidney or Heart Xenotransplantation -- 13. Defining an "acceptable risk threshold" - who should be the first kidney xenotransplant recipient? -- 14. Selection of patients for initial clinical trials of kidney xenotransplantation -- 15. Selection of patients for initial clinical trials of cardiac xenotransplantation -- 16. Selection of pediatric patients for initial clinical trials of cardiac xenotransplantation -- 17. Infection in xenotransplantation: organ-source health and patient safety -- 18. Histocompatibility testing for xenotransplantation -- Regulatory, Economic, and Social Aspects of Clinical Trials of Xenotransplantation -- 19. Xenotransplantation; the FDA perspective -- 20. Xenotransplantation: a payer's perspective -- 21. Public perceptions towards clinical trials of organ xenotransplantation -- Summation -- 22. What did the workshop achieve?
520
$a
This title provides an illuminating examination of the current state of xenotransplantation - grafting or transplanting organs or tissues between members of different species - and how it might move forward into the clinic. To be sure, this is a critical topic, as a major problem that remains worldwide is an inadequate supply of organs from deceased human donors, severely limiting the number of organ transplants that can be performed each year. Based on presentations given at a major conference on xenotransplantation, this title includes important views from many leading experts who were invited to present their data and opinions on how xenotransplantation can advance into the clinic. Attention was concentrated on pig kidney and heart transplantation as it is in regard to these organs that most progress has been made. Collectively, these chapters effectively highlight the many advantages of xenotransplantation to patients with end-stage organ failure, thereby encouraging the mapping of a concrete pathway to clinical xenotransplantation. The book is organized across 22 chapters, beginning with background information on clinical and experimental xenotransplantation. Following this are discussions addressing how pigs can be genetically engineered for their organs to be resistant to the human immune response through deletion of pig xenoantigens, and the insertion of 'protective' human transgenes. Subsequent chapters analyze complications that arise in practice, comparing allotransplant and xenotransplant rejection. The selection of the ideal patients for the first clinical trials is discussed. Finally, the book concludes with an analysis on the regulatory, economic, and social aspects of this research, including FDA perspectives and the sensitive, psychosocial factors regarding allotransplantation and xenotransplantation. A major and timely addition to the literature, Clinical Xenotransplantation will be of great interest to all researchers, physicians, and academics from other disciplines with an interest in xenotransplantation.
650
0
$a
Xenografts.
$3
791409
650
1 4
$a
Surgery.
$3
274153
650
2 4
$a
Hepatology.
$3
274979
650
2 4
$a
Microbiology.
$3
192943
650
2 4
$a
Immunology.
$3
189152
700
1
$a
Cooper, David K. C.
$3
877667
700
1
$a
Byrne, Guerard.
$3
877668
710
2
$a
SpringerLink (Online service)
$3
273601
773
0
$t
Springer Nature eBook
856
4 0
$u
https://doi.org/10.1007/978-3-030-49127-7
950
$a
Medicine (SpringerNature-11650)
筆 0 讀者評論
全部
電子館藏
館藏
1 筆 • 頁數 1 •
1
條碼號
館藏地
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
000000190101
電子館藏
1圖書
電子書
EB QR188.8 .C641 2020 2020
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
多媒體檔案
https://doi.org/10.1007/978-3-030-49127-7
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼
登入